Cabergoline

Composition:

Each film-coated tablet contains Cabergoline……………………0.5mg.

Indication:

Inhibition of physiological lactation：

LuciCaber is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons.

Treatment of hyperprolactinemic disorders：

LuciCaber is indicated for the treatment of pathological hyperprolactinaemia.

Dosage and Use:

For the prevention of onset of physiological lactation in the peurperium:
LuciCaber should be administered during the first day post-partum. The recommended therapeutic dosage is 1 mg (two 500 microgram tablets) given as a single dose.

For treatment of pathological hyperprolactinaemia:
the recommended initial dosage of LuciCaber is 500 microgram per week given in one or two (one-half of one 500 microgram tablet) doses (e.g. on Monday and Thursday) per week. The weekly dose should be increased gradually, preferably by adding 500 microgram per week at monthly intervals until an optimal therapeutic response is achieved.